Aldosterone synthase inhibition in mineralocorticoid blockade: From hypertension to cardiovascular and kidney disease.

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2025-07-11 DOI:10.1016/j.medj.2025.100772

Jonathan W Cunningham, Carolyn S P Lam

引用次数: 0

Abstract

The Advance-HTN trial demonstrated that lorundrostat, an aldosterone synthase inhibitor, effectively reduced 24-h systolic blood pressure by 8 mm Hg in resistant hypertension, with manageable hyperkalemia.¹ These findings support further research into aldosterone synthase inhibitors as promising alternatives to mineralocorticoid receptor antagonists for resistant hypertension management.

查看原文本刊更多论文

醛固酮合成酶抑制在矿物皮质激素阻断：从高血压到心血管和肾脏疾病。

Advance-HTN试验表明，lorundrostat（一种醛固酮合成酶抑制剂）可有效降低顽固性高血压患者24小时收缩压8 mm Hg，并伴有可控的高钾血症这些发现支持进一步研究醛固酮合成酶抑制剂作为矿物皮质激素受体拮抗剂治疗顽固性高血压的有希望的替代品。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.